Cleveland Research downgrades Roku (NASDAQ:ROKU) from Buy to Neutral.
Analyst Ratings for ONEOK
Within the last quarter, ONEOK (NYSE:OKE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Cleveland Research Downgrades Roku to Neutral
Cleveland Research downgrades Roku (NASDAQ:ROKU) from Buy to Neutral.
Related Posts
Raymond James Upgrades GMS to Outperform, Announces $72 Price Target
Raymond James analyst Sam Darkatsh upgrades GMS (NYSE:GMS) from Market Perform to Outperform and announces $72 price target.
Regeneron, Sanofi Report FDA Approved Dupixent As Treatment For Adults, Children Aged 12+ With Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date
Dupixent 300 mg weekly
Raymond James Maintains Strong Buy on Envestnet, Raises Price Target to $87
Raymond James analyst Patrick O'Shaughnessy maintains Envestnet (NYSE:ENV) with a Strong Buy and raises the price target from $86 to $87.